6 completed, 3 recruiting. 9 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 6, Recruiting 3 |
| Phase 2 | 4 | Completed 3, Recruiting 1 |
Follow Hypogammaglobulinemia: new trials by email Literature Review of Hypogammaglobulinemia trials Research Report on Hypogammaglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections Panzyga, 10% Intravenous Solution, Placebo - Hypogammaglobulinemia, Autoimmune Conditions | Phase 3 | Recruiting | Octapharma | 360 | 2026-06-10 | 2026-10-28 |
| A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma Xembify, Placebo - Hypogammaglobulinemia, Bacterial Infections | Phase 3 | Recruiting | Grifols Therapeutics LLC | 386 | 2022-12-26 | 2026-09-30 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin, Immunoglobulins - Haematological Malignancy, Hypogammaglobulinemia | Phase 2 / Phase 3 | Recruiting | Monash University | 300 | 2022-11-30 | 2024-04-19 |
| Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) Panzyga, Placebo - Chronic Lymphocytic Leukemia, Hypogammaglobulinemia | Phase 3 | Completed | Octapharma | 247 | 2020-10-05 | 2026-11-02 |
| Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Plerixafor, G-CSF - Myelokathexis, Infections | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2014-10-14 | 2026-06-26 |
| Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) Kedrion IVIG 10% - Primary Immunodeficiency, Agammaglobulinemia | Phase 3 | Completed | Kedrion S.p.A. | 45 | 2012-11-12 | 2021-02-16 |
| Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. Gammaplex (Intravenous immunoglobulin) - Primary Immunodeficiency, Common Variable Hypogammaglobulinemia | Phase 3 | Completed | Bio Products Laboratory | 50 | 2006-01-01 | 2013-01-24 |
| Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients IVIG-L - Hypogammaglobulinemia | Phase 2 / Phase 3 | Completed | Prothya Biosolutions | 15 | 2001-05-01 | 2007-04-19 |
| Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients CMV-Ig - Hypogammaglobulinemia | Phase 2 / Phase 3 | Completed | The Cleveland Clinic | 50 | 2001-01-01 | 2010-06-10 |
Agammaglobulinemia (9) · Infections (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Primary Immunodeficiency Diseases (2) · Bacterial Infections (1) · Common Variable Immunodeficiency (1) · Hematologic Neoplasms (1) · Hyper-IgM Immunodeficiency Syndrome (1) · Hypogammaglobulinemia, X-Linked (1) · Immunologic Deficiency Syndromes (1) · Leukemia (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Neoplasms, Plasma Cell (1)
Blood Protein Disorders (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Immunologic Deficiency Syndromes (8) · Immunoproliferative Disorders (3) · Neoplasms by Histologic Type (3) · Chronic Disease (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Cytopenia (2) · Disease Attributes (2) · Genetic Diseases, Inborn (2) · Leukemia (2)
Panzyga (2) · gamma-Globulins (2) · Amoxicillin (1) · Ciprofloxacin (1) · Clavulanic Acid (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Immunoglobulins (1) · Immunoglobulins, Intravenous (1) · Saline Solution (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · plerixafor (1)
Octapharma (2) · Bio Products Laboratory (1) · Grifols Therapeutics LLC (1) · Kedrion S.p.A. (1) · Monash University (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Prothya Biosolutions (1) · The Cleveland Clinic (1)
United States (7) · Poland (3) · Bulgaria (2) · Czechia (2) · Greece (2) · Hungary (2) · Australia (1) · Bosnia and Herzegovina (1) · Canada (1) · Croatia (1) · Denmark (1) · Germany (1) · Israel (1) · Italy (1) · Latvia (1)
David H McDermott, M.D. (1) · Jeff T Chapman, MD (1) · Melvin Berger, MD (1) · Mirella Calcinai, MD (1) · Prof Erica Wood (1) · Prof Zoe McQuilten (1)
PMID 36818468, PMID 37561579, PMID 42606118
2023 (1)